Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is a clinical-stage biopharmaceutical company pioneering the development of novel immunotherapies for the treatment of cancer. Founded on groundbreaking research from Dr. Edgar Engleman’s lab at Stanford University, the company leverages its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform to reprogram the tumor microenvironment and stimulate robust anti-cancer immune responses. This innovative approach combines tumor-targeting antibodies with immune-stimulating linker-payloads, harnessing both the innate and adaptive immune systems to deliver durable therapeutic effects.
Boltbody™ ISAC Platform Technology
The Boltbody™ ISAC platform is at the core of Bolt Biotherapeutics’ therapeutic strategy. Each ISAC candidate integrates three key components: a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant. The platform is designed to activate myeloid cells, such as macrophages, which play a pivotal role in initiating and sustaining immune responses against tumors. By releasing cytokines and chemokines, activated myeloid cells attract additional immune cells to the tumor site, creating a positive feedback loop that amplifies the anti-tumor response. This unique mechanism positions the Boltbody™ ISAC platform as a transformative technology in the field of immuno-oncology.
Pipeline and Clinical Programs
Bolt Biotherapeutics’ clinical pipeline reflects its deep expertise in myeloid biology and cancer drug development. The company’s lead candidates include:
- BDC-3042: A first-in-class agonist antibody targeting Dectin-2, designed to convert tumor-supportive macrophages into tumor-destructive macrophages. Currently in Phase 1 clinical trials, BDC-3042 is being evaluated across multiple solid tumor types.
- BDC-4182: A next-generation Boltbody™ ISAC targeting claudin 18.2, a clinically validated marker expressed in gastric, pancreatic, and other cancers. Supported by promising preclinical data, BDC-4182 is advancing toward clinical trials, with initiation expected in 2025.
- Trastuzumab imbotolimod (formerly BDC-1001): A HER2-targeting ISAC that has demonstrated early clinical efficacy and tolerability in Phase 1 trials. This program highlights Bolt’s ability to target specific tumor markers effectively.
These programs are complemented by strategic collaborations with leading biopharmaceutical companies, enabling Bolt to expand its pipeline and explore novel therapeutic combinations.
Scientific and Industry Significance
Bolt Biotherapeutics operates at the forefront of immuno-oncology, a rapidly evolving field focused on harnessing the immune system to combat cancer. By targeting both innate and adaptive immunity, the company addresses key limitations of existing therapies, such as immune evasion and tumor resistance. Its focus on myeloid biology, a relatively underexplored area in oncology, sets it apart from competitors and positions it as a potential leader in macrophage-targeted therapies. Additionally, the company’s Stanford-originated technology and strong investor backing underscore its scientific credibility and growth potential.
Challenges and Opportunities
Like all clinical-stage biopharmaceutical companies, Bolt Biotherapeutics faces challenges such as regulatory approval processes, competition from other immunotherapy developers, and the inherent risks of clinical trials. However, its differentiated platform, promising pipeline, and strategic collaborations provide a strong foundation for overcoming these obstacles. The company’s ability to generate durable therapeutic responses and address unmet medical needs in oncology represents a significant opportunity for both patients and investors.
Conclusion
Bolt Biotherapeutics, Inc. is redefining cancer treatment through its innovative Boltbody™ ISAC platform and deep expertise in myeloid biology. With a robust clinical pipeline, strategic industry partnerships, and a commitment to scientific excellence, the company is well-positioned to make a meaningful impact in the fight against cancer. Its focus on leveraging both innate and adaptive immunity offers a unique approach to addressing complex challenges in oncology, making it a key player to watch in the biopharmaceutical landscape.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, announced its participation in two key conferences in February 2023. Management will engage in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Day on February 8 at 12:55 p.m. PST, followed by another chat at the Virtual SVB Securities Global Biopharma Conference 2023 on February 16 at 12:40 p.m. PST. Live webcasts of these events will be available on Bolt's website, with archived replays accessible for 30 days post-event. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on its pipeline candidates, including BDC-1001 and BDC-3042.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) has appointed Laura Berner to its Board of Directors as of December 14, 2022. Laura brings extensive experience in biopharmaceuticals, having executed over 50 transactions in her career. Her strategic insights are expected to support Bolt's ongoing development of its immunotherapy pipeline, particularly BDC-1001, which is advancing into Phase 2 clinical trials, and BDC-3042, slated for clinical evaluation. CEO Randall Schatzman expressed enthusiasm for her contributions, highlighting her potential to enhance Bolt's commitment to cancer treatment.
Bolt Biotherapeutics (BOLT) reported third-quarter 2022 results, highlighting the dose-escalation trials for BDC-1001 targeting HER2-expressing tumors, with recruitment on track for completion by year-end 2022. Collaboration revenue rose to $2.1 million, a 50% increase from the previous quarter. R&D expenses remained stable at $19.0 million, while G&A expenses increased to $5.5 million. The company’s cash balance stands at $209.6 million, expected to fund operations through 2025. Upcoming milestones include topline data from BDC-1001 and the initiation of BDC-3042 clinical studies in 2023.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) presented new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 SITC Annual Meeting in Boston. The innovative therapy aims to convert immunosuppressive tumor-associated macrophages into immunostimulatory cells, potentially enhancing anti-tumor immunity. Key findings include BDC-3042's ability to selectively activate these macrophages, thereby facilitating anti-tumor activity in preclinical models. Bolt is advancing BDC-3042 through IND-enabling studies as part of its commitment to developing novel cancer immunotherapies.
Bolt Biotherapeutics (Nasdaq: BOLT) will participate in the Stifel 2022 Healthcare Conference on Nov. 16, 2022, at 1:15 p.m. EST in New York. The event will feature a fireside chat with management, and a live webcast can be accessed on Bolt's website. The company is known for developing innovative immuno-oncology therapeutics, including BDC-1001 and BDC-3042, which target HER2 and modulate myeloid biology, respectively. Archived replays will be available for 30 days post-event.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focusing on immuno-oncology, announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.
The event will take place on September 13, 2022, at 12:20 p.m. ET in New York City. A live webcast will be accessible on Bolt's website, with archived replays available for 30 days post-event.
Bolt's pipeline includes innovative therapies targeting cancer, highlighting their commitment to advancing treatment options.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2022 financial results, highlighting $223.6 million in cash to fund operations through 2025. Clinical progress includes the ongoing BDC-1001 dosage studies, with anticipated data readouts later this year. The company has prioritized its pipeline, ceasing BDC-2034 due to off-target toxicity, while focusing on BDC-1001 and BDC-3042. Collaboration revenue rose to $1.4 million, a 75% increase from Q1 2022. R&D expenses fell slightly to $18.9 million, while G&A expenses rose to $5.5 million.
Bolt Biotherapeutics announces a presentation at the 2022 ASCO Annual Meeting in Chicago, showcasing data on myeloid cell presence in solid tumors, even with low T cell infiltration. The poster, titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)," highlights myeloid cells' potential as therapeutic targets. The insights could enhance the efficacy of myeloid-targeted therapies, benefiting patients resistant to T cell approaches. The abstract number is 2557, and the poster session is scheduled for June 5.
Bolt Biotherapeutics reported Q1 2022 financial results, showing collaboration revenue of $0.8 million, driven by R&D partnerships. R&D expenses rose to $18.4 million, reflecting progress in clinical trials and IND-enabling activities. General and administrative expenses increased to $6.3 million. The company holds a robust cash balance of $246.8 million, expected to fund operations and key milestones into 2024. The lead program, BDC-1001, is on track for data readouts in H2 2022, with promising early signs of clinical disease control.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotech firm, will present an overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 12:45 p.m. PT. The presentation will highlight Bolt's innovative immuno-oncology therapeutics that utilize Boltbody™ to target tumors. Key products include BDC-1001, a HER2-targeting agent in a Phase 1/2 trial, and others targeting CEA and Dectin-2. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
What does Bolt Biotherapeutics specialize in?
What is the Boltbody™ ISAC platform?
What are Bolt Biotherapeutics' lead clinical candidates?
How does Bolt Biotherapeutics differentiate itself in the immuno-oncology space?
What are the potential challenges faced by Bolt Biotherapeutics?
What types of cancer does Bolt Biotherapeutics target?
What partnerships does Bolt Biotherapeutics have?
What is BDC-3042?
What is BDC-4182?
What is the significance of Bolt Biotherapeutics' Stanford-originated technology?
